THK-5351
Phase 2Small molecule
THK-5351 is one of 84 small molecule programs targeting Neurodegenerative Disease. It is currently in Phase 2.
3
Indications
4
Total Trials
0
Active Trials
83
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
461 competitors in Stroke
#DrugCompanyPhaseTrials
1Activase
RochePreclinical
Folvite
Eli LillyPreclinical
THK-5351
JJae Seung Kim
Phase 2
Botox
RRevance Therapeutics, Inc.
Preclinical
Zantac 150
CChattem
Preclinical
Alka-Seltzer
AAbbott
Preclinical
Haldol
DDePuy Orthopaedics
Preclinical
Direct Anticoagulant
BayerPreclinical
Inderal
Mylan Pharmaceuticals IncPreclinical
Carbidopa-Levodopa
Neurocrine BiosciencesPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cognition1 trial
The Aging Brain and Cognition: Contribution of Vascular Injury, Amyloid Plaque and Tau Protein to Cognitive Dysfunction After Stroke
Completed·—·Phase 2·NCT04588649·181 enrolled
Stroke1 trial
The Influence of Sequential Tau Protein and Amyloid Plaque Imaging Changes on Stroke Prognosis and Cognitive Outcome
Unknown status·—·Phase 2·NCT04572477·200 enrolled
Neurodegenerative Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for THK-5351. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- JJae Seung Kim